

Date		

PRIOR AUTHORIZATION QUESTIONNAIRE-Sutent® (sunitinib)

M.D. Last Name:	M.D. First Nar	ne:		
Physician Phone:	Physician Fax	: 		
Patient				
**FAILURE TO COMPLETE THE FORM MAY	RESULT IN AN AUTOMATIC DENIAL (C	HART NOTES ARE REQ	UIRED)*	*
 Diagnosis: Gastrointestinal stromal tumor (GIST) (ID) Advanced renal cell carcinoma (Proceed) Other* (please specify): *If diagnosis of "Other" is used, please and in the please of the plea	d to Question #3)	safety data supporting	this real	ıest
Has the patient experienced disease progre	•		No No	2001
B. Does the patient have a hypersensitivity to sunitinib or any other component of Sutent [®] ?		Yes	No	
4. Is the prescribing physician an oncologist?			Yes	No
Has the patient presented with a cardiac ev	rent within the past 12 months?		Yes	No
a. If Yes, please specify:				
6. Baseline LVEF:				
7. Dose requested:				
8. Strength requested:				
☐ 12.5 mg ☐ 25 mg	☐ 50 mg			
Continuation of therapy: 9. Has the patient demonstrated an improved	health-related quality of life or a decrease	in disease progression?	Yes	No
10. Current LVEF:				
11. Physician Signature or name of person pro	viding answers			
This medication may be dispensed through a enrollment.	a Specialty Pharmacy, please provide th	ne patient's phone numb	er for p	roper
Patient's phone number:				
Physician Comments				
Send or Fax completed form to:	RESTAT 11900 W. Lake Park Dr. Milwaukee, WI 53224	QUESTIONS PLEASE (

*****DISCLOSURE STATEMENT****

877-329-7279

www.restat.com

877-526-9906